FDA to clarify rules on advisory committee membersBMJ 2006; 333 doi: http://dx.doi.org/10.1136/bmj.333.7562.278 (Published 03 August 2006) Cite this as: BMJ 2006;333:278
- Janice Hopkins Tanne
- New York
The US Food and Drug Administration announced last week that it is to develop guidelines to clarify the relationships between members of its advisory committees and pharmaceutical companies. The aim is to make advisory committee processes more effective and to reassure the public about the integrity of the process.
There will be a period for public comment on the proposed new rules.
Some scientists with industry ties are granted waivers to allow them to participate in advisory committees, but the process is unclear.
The advisory committees provide expert advice and recommend …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial